Showing 65,021 - 65,040 results of 99,862 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (nn decrease)) ))', query time: 1.20s Refine Results
  1. 65021

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  2. 65022

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  3. 65023

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  4. 65024

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  5. 65025

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  6. 65026

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  7. 65027

    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  8. 65028

    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  9. 65029

    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  10. 65030

    Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  11. 65031

    Alterations in neural proliferation caused by LOF and GOF of <i>pros</i>. by Jordi Colonques (222976)

    Published 2011
    “…<p>A–I. Confocal projections taken through the OL of <i>w</i>t, <i>pros<sup>v24</sup></i>, and <i>hsGal4;UAS-pros</i> late third instar larvae from a ventro-anterior orientation showing immunostaining for PROS, BrdU and PH3, as indicated. …”
  12. 65032

    DataSheet1_Fabrication and characterization of polycaprolactone/chitosan nanofibers containing antibacterial agents of curcumin and ZnO nanoparticles for use as wound dressing.pdf by Pezhman Mosallanezhad (13847908)

    Published 2022
    “…SEM images confirmed the nanofibrous structure of samples with 100 ± 5 to 212 ± 25 nm in average diameter. Elemental analysis of nanofibers showed a good distribution of ZnO along nanofibers which not only caused decreasing in nanofiber diameter but also increased tensile strength of nanofibers up to 2.9 ± 0.5 MPa and with good elongation at break of 39 ± 2.9. …”
  13. 65033

    Supplementary Material for: Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma by Chang C.V. (4161655)

    Published 2016
    “…The RT-qPCR array showed an increased expression of <i>MKI67,</i><i>OCT4</i>/<i>POU5F1,</i> and <i>DLL4 </i>in all tumours. <i>NANOG </i>was decreased in ACP. …”
  14. 65034

    Histologic analysis of bone erosions in mice with collagen-induced arthritis (CIA) after treatment with IFN-β by Judith van Holten (26438)

    Published 2011
    “…Sections were scored on a 4-point scale. RANKL staining; a decrease of RANKL-positive cells was observed in the group of animals treated with 2.5 μg IFN-β, although not statistically significant (= 0.07). c-Fos staining; the number of c-Fos-positive cells was significantly reduced in the mice treated with daily 2.5 μg per injection IFN-β (= 0.04). …”
  15. 65035

    Data_Sheet_1_Network analysis of live pig movements in North Macedonia: Pathways for disease spread.pdf by Kathleen C. O'Hara (11769671)

    Published 2022
    “…Movements to slaughterhouses predominated (85.6%), with movements between farms (5.4%) and movements to market (5.8%) playing a lesser role. …”
  16. 65036

    Video_2_An Observation-Based Study of Gulf Stream Meander Kinematics Offshore of Cape Hatteras.mp4 by Mike Muglia (12910745)

    Published 2022
    “…Downstream currents occupy an increasing portion of the water column as a crest approaches, and a decreasing fraction as a trough approaches. …”
  17. 65037

    Video_1_An Observation-Based Study of Gulf Stream Meander Kinematics Offshore of Cape Hatteras.mp4 by Mike Muglia (12910745)

    Published 2022
    “…Downstream currents occupy an increasing portion of the water column as a crest approaches, and a decreasing fraction as a trough approaches. …”
  18. 65038

    Effect of microRNAs in fate determination of memory CD8 T cells. by Gonzalo Almanza (246998)

    Published 2010
    “…↑and↓ refer to net increase/decrease from the corresponding baseline values. Δ refers to a variation between IL-15-derived and IL-2-derived memory T cells at corresponding time points. …”
  19. 65039

    The ability of MLR-Tregs to allospecifically suppress MLR proliferation. by Yuming Yu (212650)

    Published 2011
    “…Note the drastic decrease in the inhibitory effect by MLR-Tregs in the non-specific culture combinations as the modulator cell concentrations decreased (** = p<0.01; n = 5).…”
  20. 65040

    SP-D agglutinates and inhibits infectivity of HIV. by Jens Madsen (391091)

    Published 2013
    “…<b>C</b>: Infectious HIV BaL particles were preincubated at a pH of 7.4 (black) or 5.0 (white) in the presence and absence of the indicated concentrations of SP-D (1–10 µg/mL) before inoculation with PM1 cells. …”